Xiamen University
33
2
7
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 33 trials
100.0%
+13.5% vs industry average
24%
8 trials in Phase 3/4
0%
0 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (33)
Effects Of App-Supported Transitional Care On Neurogenic Bladder In Spinal Cord Injury Patients
Role: lead
The Combined Multicomponent Intervention Specifically in Rural Community Older Adults at High Risk for Mild Cognition Impairment
Role: collaborator
Decision Aid for Women Newly Diagnosed With Breast Cancer
Role: lead
Effectiveness of Large Language Model-Based Chatbot Among Parents of Junior High School Girls in Improving Human Papillomavirus (HPV) Vaccine Awareness, Intention and Vaccination Rates
Role: lead
Effectiveness of Large Language Model-Based Chatbot Among Female University Stdents in Improving HPV Vaccine Awareness, Intention and Vaccination Rates
Role: lead
Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy
Role: collaborator
Narrative Nursing for Cesarean Mothers' Anxiety and Breastfeeding Confidence
Role: collaborator
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Role: lead
HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR
Role: collaborator
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
Role: lead
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
Role: lead
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Role: lead
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Role: lead
A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ
Role: collaborator
Diabetes Complication Control in Community Clinics (D4C) Trial
Role: collaborator
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
Role: lead
Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
Role: collaborator
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Role: lead
A Multicenter Observational Cohort of Degenerative Spine Diseases in China（DSDC）
Role: lead
Effect of Multimodal Prehabilitation After Colorectal Cancer Surgery
Role: lead